Immunoglobulin, Antibody, Or Fragment Thereof, Other Than Immunoglobulin Antibody, Or Fragment Thereof That Is Conjugated Or Adsorbed Patents (Class 530/387.1)
  • Patent number: 11385242
    Abstract: Provided is a composition including a combination of at least one short peptide and at least one peptide dimer, in defined ratio, to which autoantibodies found in elevated levels in schizophrenic patients bind.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: July 12, 2022
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Meir Shinitzky, Ludmila Schechtman
  • Patent number: 11352427
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the T Cell Immunoglobulin and Mucin Protein-3 (TIM-3). The invention provides a TIM-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the TIM-3-binding agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: June 7, 2022
    Assignee: ANAPTYSBIO, INC.
    Inventors: Marilyn Kehry, David J. King, Jean Da Silva Correia
  • Patent number: 11353454
    Abstract: Isolated peptides that include one or more antigenic sites of Zika virus (ZIKV) and methods of their use and production are disclosed. The peptides can be used, for example, to detect exposure of a subject to a flavivirus infection, such as a ZIKV infection.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: June 7, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Surender Khurana
  • Patent number: 11345745
    Abstract: The present invention provides an antibody that can bind to targets with greater affinity. A flexible antibody-like molecule having a nonpeptide hinge part comprising: a group having a nonpeptide hinge part represented by a general formula (I): XY-Asp-Lys-Thr-His-Thr (SEQ ID No. 1)—wherein X represents an amino acid or a peptide composed of 2 to 50 amino acid residues, and Y represents for a group having an alkyleneoxide; and an antibody Fc fragment bound to the group having a nonpeptide hinge part.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: May 31, 2022
    Assignee: BIOMOLECULAR HOLDINGS LLC
    Inventor: Daniel J. Capon
  • Patent number: 11345729
    Abstract: The present disclosure relates to a novel recombinant BAF57 fusion protein and the use thereof as a composition capable of effectively preventing or treating inflammatory disease, immune-related disease or cancer. The fusion protein provided in the present disclosure may be delivered into cells, bind to BAF155 or other BAF complex subunit, and act as a competitive inhibitor of BAF57 present in the cell, thereby lowering the expression level of BAF57 by a protein degradation mechanism, thereby effectively preventing, ameliorating or treating various diseases such as inflammatory disease, immune-related disease or cancer.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: May 31, 2022
    Assignee: GOOD T CELLS, INC.
    Inventors: Jung Ho Kim, Beom Seok Kim
  • Patent number: 11325964
    Abstract: A process for the preparation of pharmaceutically acceptable immunoglobulin compositions from plasma-derived immunoglobulin fractions which allows the parallel preparation of immunoglobulin compositions enriched in IgG, IgM and IgA. In this process, immunoglobulin contained in Cohn fraction I/II/III or Kistler Nitschmann fraction A+I is resolubilized at conductivities of at least 1 mS/cm, and following removal of contaminating protein the resolubilized immunoglobulin is subjected to anion exchange chromatography to obtain IgG- and IgM/IgA-enriched immunoglobulin compositions. The IgG-enriched immunoglobulin composition is further subjected to treatment with a cation exchange material to obtain an immunoglobulin composition having a reduced properdin content.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: May 10, 2022
    Assignee: BIOTEST AG
    Inventors: Oliver Maneg, Achim Hannappel, Alexander Moehlenkamp-Roettger, Wolfgang Moeller, Dieter Rudnick
  • Patent number: 11318194
    Abstract: An immunogenic polypeptide selected from an isolated Clostridium perfringens pilus polypeptide, a variant of the pilus polypeptide; a fragment of the pilus polypeptide; and a fragment of the variant, is useful for the preparation of a vaccine for the treatment or prevention of enteric necrosis in poultry. The isolated Clostridium perfringens pilus polypeptide includes an assembled pilus or the pilus subunits CnaA, FimA and/or FimB.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: May 3, 2022
    Assignee: HER MAJESTY THE QUEEN IN RIGHT OF CANADA, AS REPRESENTED BY THE MINISTER OF AGRICULTURE AND AGRI-FOOD
    Inventors: Jianhua Gong, Dion Lepp
  • Patent number: 11292814
    Abstract: The present invention provides improved methods of protein purification using CEX chromatography. Such methods generally comprise the steps of: contacting a protein of interest (e.g., an antibody) with a cation exchange resin at a first pH, that is less than the pI of the most acidic isoform of the protein of interest, such that the protein of interest binds to the resin; washing the cation exchange resin at a second pH that is greater than the first pH, but less than the pI of the most acidic isoform of the protein of interest; and eluting the protein of interest from the resin at a third pH that is about equal to or less than the first pH. The methods of the invention are particularly useful for the commercial purification of recombinant therapeutic proteins (e.g., antibodies).
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: April 5, 2022
    Assignee: E.R. SQUIBB & SONS, L.L.C.
    Inventors: Alahari Arunakumari, Jue Wang
  • Patent number: 11274157
    Abstract: The present application provides constructs comprising an antibody moiety that specifically binds to a complex comprising a histone H3 peptide and an MHC class I protein. Also provided are methods of making and using these constructs.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: March 15, 2022
    Assignee: EUREKA THERAPEUTICS, INC.
    Inventors: Vivien Wai-Fan Chan, Hong Liu, Yoko Nakano, Yiyang Xu
  • Patent number: 11267865
    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of red blood cells or a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: March 8, 2022
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg, Erik M. Vogan
  • Patent number: 11262364
    Abstract: Provided is a composition including a combination of at least one short peptide and at least one peptide dimer, in defined ratio, to which autoantibodies found in elevated levels in schizophrenic patients bind.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: March 1, 2022
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Meir Shinitzky, Ludmila Schechtman
  • Patent number: 11261247
    Abstract: Antibodies that modulate insulin receptor signaling are provided.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: March 1, 2022
    Assignee: XOMA (US) LLC
    Inventors: John Corbin, Mark Leslie White, Susan R. Watson, Vinay Bhaskar
  • Patent number: 11220543
    Abstract: The present invention relates to an anti-CD66c antibody and its use for treating cancer, and more particularly, it is possible to induce T-cell activation or humoral immune response using an antibody specifically recognizing CD66c. A nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector comprising the nucleic acid molecule, a host cell and the antibody or antigen-binding fragment thereof is used for alleviation, prevention, treatment or diagnosis of CD66c-related disease.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: January 11, 2022
    Assignee: DINONA
    Inventors: Sangsoon Yoon, Kwon Pyo Hong, Soseul Kim, Gil Yong Ji, Young Hoon Lim
  • Patent number: 11198719
    Abstract: The present disclosure relates to compositions of insulin-Fc fusion proteins and their use to treat diabetes.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: December 14, 2021
    Assignee: Akston Biosciences Corporation
    Inventors: Todd C. Zion, Thomas M. Lancaster
  • Patent number: 11192919
    Abstract: The invention provides for the removal of a large fraction of contaminants from protein preparations while maintaining a high level of recovery using tentacle anion exchange matrix chromatography medium. Using the methods of the invention, leached affinity chromatography contaminants can be removed from recombinant protein preparations.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: December 7, 2021
    Assignee: AMGEN INC.
    Inventors: Samuel Ray Trejo, Robert Perry Brake
  • Patent number: 11168136
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: November 9, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
  • Patent number: 11170888
    Abstract: Embodiments of the invention include systems and methods for capturing crowd wisdom to be tested for individualized treatment plans. These systems and methods include data mining crowd sourced health related information and unstructured medical narratives and storytelling to identify treatment plans and general techniques that individuals with chronic diseases/symptoms, including but not limited to IBD and other immune invisible neglected and stigmatized diseases, use to improve their general health and wellbeing. A system for testing the treatments effectiveness in a population and then in an individual is also disclosed.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: November 9, 2021
    Assignee: VIVANTE HEALTH, INC.
    Inventor: Kimon Angelides
  • Patent number: 11168135
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: November 9, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
  • Patent number: 11155626
    Abstract: The present invention relates to the biomedicine field, in particular to an anti-human PD-L1 humanized monoclonal antibody and its applications. The invention obtains an anti-human PD-L1 humanized monoclonal antibody with good specificity, high affinity and stability by screening, and the antibody can specifically bind to human PD-L1 instead of binding to members of B7 family, and it can bind to active T-cells to strengthen the activation of T-cells, so it can significantly inhibit the growth of tumor.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: October 26, 2021
    Assignee: REYOUNG (SUZHOU) BIOLOGY SCIENCE & TECHNOLOGY CO., LTD
    Inventors: Yixiang Zhu, Shuhua Guo, Jiachun Zhang, Ge Li
  • Patent number: 11155630
    Abstract: The present invention relates to bispecific antibodies that specific bind to BCMA (B-Cell Maturation Antigen) and CD3 (Cluster of Differentiation 3). Method of making the bispecific antibodies and method of using the bispecific antibodies for the treatment of multiple myeloma are also provided.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: October 26, 2021
    Assignee: PFIZER INC.
    Inventors: Tracy Chia-Chien Kuo, Javier Fernando Chaparro Riggers, Wei Chen, Amy Shaw-Ru Chen, Edward Derrick Pascua, Thomas John Van Blarcom, Leila Marie Boustany, Weihsien Ho, Yik Andy Yeung, Pavel Strop, Arvind Rajpal
  • Patent number: 11136377
    Abstract: In certain embodiments, this present invention provides antibodies and Fc fusion proteins with enhanced pharmacokinetics, such as biotinylated antibodies or biotinylated Fc fusion polypeptides.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: October 5, 2021
    Assignee: THE JACKSON LABORATORY
    Inventors: Derry Roopenian, Gregory Christianson
  • Patent number: 11136390
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: June 11, 2016
    Date of Patent: October 5, 2021
    Assignee: ALECTOR LLC
    Inventors: Kate Monroe, Helen Lam, Francesca Avogadri-Connors, Seung-Joo Lee, William Monteith, Herve Rhinn, Arnon Rosenthal
  • Patent number: 11124576
    Abstract: It is intended to provide a method for efficiently and stably producing a heteromultimer by incubating, under a reducing condition, homo variants of plural types of polypeptides in which the alteration of amino acids that form the interface between Fc regions and/or the alteration to destabilize the stability of a heavy chain CH3 region has been introduced in the heavy chain CH3 regions so at to achieve the promotion of the dissociation of the Fc regions and/or the control of the association thereof through the use of charge repulsion.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: September 21, 2021
    Assignee: Chungai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Hitoshi Katada, Futa Mimoto
  • Patent number: 11091548
    Abstract: The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: August 17, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Seung Chu, Dilki Wickramarachichi, John Desjarlais
  • Patent number: 11084879
    Abstract: Death receptor 5 (DR5) agonist compositions and methods for treating pancreatitis have been developed. The compositions include Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL), its analogues, and anti-DR5 agonistic antibodies. In certain embodiments, TRAIL analogs and anti-death receptor 5 agonistic antibodies have analgesic and disease modifying effects on the pancreas.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: August 10, 2021
    Assignee: The Johns Hopkins University
    Inventors: Seulki Lee, Martin G. Pomper, Ogyi Park, Magdalena Scully, Pankaj J. Pasricha
  • Patent number: 11072646
    Abstract: The present invention relates to a novel epitope that converts T cell to type 1 helper T (TH1) cell. Specifically, the present invention relates to an epitope constituting the 56th to 65th amino acids (SEQ ID No. 2) of extracellular domain (ECD) of activation-inducible tumor necrosis factor receptor (AITR), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting T cell to TH1 cell and a method for converting T cell to TH1 cell, a pharmaceutical composition comprising the antibody for preventing or treating cancer, a method for treating cancer using the antibody, a composition comprising the antibody for enhancing immunity, and a method for enhancing immunity using the antibody.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: July 27, 2021
    Assignee: Eutilex Co., Ltd.
    Inventors: Byoung S. Kwon, Seung-Joo Lee
  • Patent number: 11059874
    Abstract: The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses, bacteria, fungi, protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: July 13, 2021
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Michael Super, Jeffrey Charles Way, Donald E. Ingber
  • Patent number: 11052165
    Abstract: The invention discloses a method for virus clearance of a cell culture medium, comprising the steps of: i) providing a bulk medium portion, comprising amino acids and glucose, and a first additive portion, comprising vitamins in aqueous solution; ii) subjecting the bulk medium portion to a high temperature short time treatment (HTST); iii) passing the first additive portion through a virus retentive filter or an ultrafilter; and iv) after steps ii) and iii), mixing the bulk medium portion with the first additive portion to obtain a cell culture medium.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: July 6, 2021
    Assignee: Global Life Sciences Solutions USA LLC
    Inventors: Andreas Castan, Colin R. Tuohey
  • Patent number: 11046769
    Abstract: The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: June 29, 2021
    Assignee: COMPASS THERAPEUTICS LLC
    Inventors: Bing Gong, Rachel Rennard, Amanda Frank Oliphant, Cheuk Lun Leung, Benjamin Jacob Wolf, Ugur Eskiocak, Pearl Bakhru, Diana I. Albu
  • Patent number: 11046784
    Abstract: The present inventors discovered that the half-life in blood of an IgG antibody which is a polypeptide comprising an FcRn-binding domain can be controlled by controlling the surface charge through modification of residues exposed on the surface among residues in the variable regions of the IgG antibody. Antibodies whose half-life in blood had been controlled by the methods of the present invention were confirmed to actually retain the original activity. The methods of the present invention are widely applicable to polypeptides comprising an FcRn-binding domain, such as IgG antibodies, which are recycled via the FcRn salvage pathway regardless of the type of target antigen.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: June 29, 2021
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Hiroyuki Tsunoda, Tatsuhiko Tachibana
  • Patent number: 10993459
    Abstract: A method for unlocking bioactive proteins that can then be used to activate natural remedies. The method includes starting with Silica salt and water mixture. Then a base of whey protein concentrate is added to the mixture. The pH of the whey protein mixture is raised using a base. The pH is held at a level above 11 for at least two hours. After at least two hours an acid is then added to the mixture to bring the pH of the mixture below 3 pH. This will stop the activation process. After the unattached proteins are removed the protein mixture is then brought back to a normal pH level, around 4 pH.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: May 4, 2021
    Inventor: Ralph Yoder
  • Patent number: 10982006
    Abstract: The present invention relates to novel antigen binding domains and heterodimeric antibodies that bind Fibroblast Activation Protein (FAP).
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: April 20, 2021
    Assignee: Xencor, Inc.
    Inventors: John Desjarlais, Alex Nisthal, Seung Chu
  • Patent number: 10975157
    Abstract: The invention provides antibodies immunoreactive with human OX40 and methods of using the same. The antibodies are reactive with a portion of the C-terminus of the human OX40 protein that includes amino acids 266-277. The antibodies are useful for detecting OX40 protein expression in human tissue samples, including by immunohistochemistry, immunofluorescence, or immunoblot.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: April 13, 2021
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Yifei Zhu, Zhiming Liao, Robert Pytela
  • Patent number: 10975163
    Abstract: The present invention provides compositions and methods for increasing the permeability of a stroma around a neoplasm, and particularly to cancer cells associated with solid tumors. In one embodiment, combining a therapeutic IgE antibody with an anti-cancer agent in accordance with the invention increases the delivery of the anticancer agent to the site of, for example, a solid tumor in a subject. In one embodiment, combining a therapeutic IgE antibody with an anti-cancer agent in accordance with the invention potentiates a tumor's responsiveness and sensitivity to the anti-cancer agent.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: April 13, 2021
    Inventors: Ragupathy Madiyalakan, Christopher F. Nicodemus, Michael A Hollingsworth
  • Patent number: 10927183
    Abstract: Provided are antibodies and antigen-binding fragment thereof that bind to VSIG4. Various in vitro and in vivo methods and compositions related to antibodies. Methods include prevention and/or therapeutic treatment of cancer using an antibody or an antigen-binding fragment that binds to VSIG4.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: February 23, 2021
    Assignee: Eutilex Co., Ltd.
    Inventors: Byoung S. Kwon, Hye Jeong Kim, Sunhee Hwang, Joongwon Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Hyeok-Jun Park
  • Patent number: 10918971
    Abstract: The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: February 16, 2021
    Assignee: Cytiva BioProcess R&D AB
    Inventor: Sophia Hober
  • Patent number: 10889644
    Abstract: The present invention provides for a humanized anti-BAG3 antibody or a fragment thereof, pharmaceutical compositions comprising said antibody and its use as a medicament, in particular for use in the treatment of pancreatic tumours or other pathologies of an immune, inflammatory, neoplastic, cardiovascular and/or degenerative nature.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 12, 2021
    Assignee: BIOUNIVERSA S.R.L.
    Inventors: Maria Caterina Turco, Alessandra Rosati, Vincenzo De Laurenzi, Gianluca Sala
  • Patent number: 10875911
    Abstract: The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: December 29, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gavin Thurston, Christopher Daly
  • Patent number: 10865253
    Abstract: Novel rodent bispecific heterodimeric proteins, such as rodent bispecific antibodies, in vitro method for producing such, and uses thereof.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: December 15, 2020
    Assignee: GENMAB A/S
    Inventors: Aran F. Labrijn, Joyce I. Meesters, Janine Schuurman, Paul Parren, Anthony Armstrong, Matthew Bunce, Mark Chiu, Thomas Nesspor, Adam Zwolak
  • Patent number: 10842881
    Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates) comprising specific acyl donor glutamine-containing tags and amine donor agents. The invention also provides methods of making such engineered polypeptide conjugates using transglutaminase and methods of using thereof.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: November 24, 2020
    Assignee: Rinat Neuroscience Corp.
    Inventors: Santiago Esteban Farias, Meritxell Galindo Casas, Pavel Strop
  • Patent number: 10808026
    Abstract: Provided herein are monoclonal antibodies against Olfml-3. In some aspects, methods for treating angiogenesis-related conditions, such as cancer, are provided comprising administering an Olfml-3-binding antibody of the embodiments.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: October 20, 2020
    Assignee: Research Development Foundation
    Inventors: Beat A. Imhof, Marijana Miljkovic-Licina, Philippe Hammel
  • Patent number: 10752695
    Abstract: The present invention relates to novel stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: August 25, 2020
    Assignee: Genmab A/S
    Inventors: Jan Van De Winkel, Tom Vink, Janine Schuurman, Paul Parren, Rob Aalberse, Marijn Van Der Neut Kolfschoten
  • Patent number: 10745470
    Abstract: The present invention relates to improved antibodies specific for Tenascin-C (TnC), in particular domain specific anti-TnC antibodies with improved cross-species reactivity. In addition, the invention relates to polynuleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies and methods of using them in the treatment of disease.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: August 18, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ralf Hosse, Ekkehard Moessner, Pablo Umana
  • Patent number: 10738078
    Abstract: In certain embodiments, the invention provides a method of purifying a protein of interest from a mixture which comprises the protein of interest and one or more contaminants, comprising: a) subjecting the mixture to a first chromatography step; b) recovering the protein of interest in an elution solution; c) adding caprylic acid to the elution solution to form a contaminant precipitate; d) removing the contaminant precipitate from the elution solution; and e) subjecting the post-precipitated elution solution to a second chromatography column, thereby purifying the protein of interest.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: August 11, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ji Zheng, Jue Wang
  • Patent number: 10738133
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: August 11, 2020
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Patent number: 10732182
    Abstract: The present invention relates to methods of determining cancer cell sensitivity to treatment by using antibodies that specifically bind to and detect the presence of a Bcl-2 heterodimer protein, or a caspase and an inhibitor of caspase-IAP heterodimer protein in the cell. The methods provide a predictive tool to identify patients likely to respond to drugs that perturb heterodimer binding and induce apoptosis in a cancer cell. The invention also provides a method of predicting therapeutic efficacy in a cancer patient.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: August 4, 2020
    Assignee: Eutropics Pharmaceuticals, Inc.
    Inventor: Michael H. Cardone
  • Patent number: 10722569
    Abstract: Some aspects of this disclosure provide engineered exopolysaccharide-associated proteins, engineered bacteria expressing such proteins, and engineered biofilms comprising such proteins. Some aspects of this disclosure provide methods for engineering exopolysaccharide-associated proteins, and for the generation of engineered bacteria and biofilms expressing or comprising such proteins. Some aspects of this disclosure provide compositions and methods useful for the generation of vaccines and the vaccination of subjects, for delivering molecules of interest to a target site, for example, a surface, for purification of molecules of interest, for example, from bioreactors comprising engineered bacteria as provided herein, and for bioremediation applications, such as the cleanup of environmental pollutants.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: July 28, 2020
    Assignee: Children's Medical Center Corporation
    Inventor: Paula I. Watnick
  • Patent number: 10676528
    Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for TSLPR, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of a proliferative disorder, e.g., cancer, in a mammal and methods of treating or preventing a proliferative disorder, e.g., cancer, in a mammal are also disclosed.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: June 9, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Haiying Qin, Terry J. Fry
  • Patent number: 10668149
    Abstract: The present invention relates to combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: June 2, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Parul Doshi, Henk M. Lokhorst, Tuna Mutis
  • Patent number: 10670604
    Abstract: The present invention belongs to the field of immunology and molecular biology, which relates to an anti-PCSK9 antibody, the pharmaceutical composition and method of use thereof. In particular, the present invention relates to the monoclonal antibody, which can bind PCSK9 specifically, block association of PCSK9 with LDLR, upregulate the amount of LDLR on cell surface, heighten the metabolism of LDL cholesterol and/or triglycerides, and prevent/treat cardiovascular diseases caused by hypercholesterolemia.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: June 2, 2020
    Assignee: AD Pharmaceutical Co., Inc.
    Inventors: Baiyong Li, Zhongmin Wang, Yu Xia, Peng Zhang, Wuxian Ren, Jinan Jiao, Yuanyuan Xu, Dongsheng Dai